BERLIN — German biotech business CureVac stated Tuesday it hasactually submitted a patent violation suit versus competitor BioNTech for work that it states contributed to the advancement of the BioNTech-Pfizer coronavirus vaccine. BioNTech stated its work is initial and it would “vigorously” contest the claim.
CureVac, which last year reported frustrating results from late-stage screening of its own first-generation COVID-19 shot, earlier this year began a scientific trial of a second-generation vaccine prospect established with British pharmaceutical business GSK.
The business stated it was lookingfor “fair settlement” from BioNTech for the declared violation, however it didn’t pointout an quantity.
CureVac stated it would not pursue a court injunction and doesn’t “intend to take legal action that restrains the production, sale or circulation” by BioNTech and partner Pfizer of